Clinical Scorecard: FDA Updates SMA Treatment Dosing

At a Glance

Key Highlights

• Higher-dose regimen approved with increased drug exposure during loading and maintenance phases.
• Two 50 mg loading doses administered 14 days apart, followed by maintenance doses of 28 mg every 4 months.
• Statistically significant improvement in motor function in treatment-naïve infants compared to untreated group.
• Safety profile consistent with lower-dose regimen; common adverse events include pneumonia and malnutrition.
• Monitoring for bleeding complications and kidney damage is recommended.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of spinal muscular atrophy based on clinical evaluation and genetic testing.

Management

• Initiate treatment with nusinersen using the approved high-dose regimen.

Monitoring & Follow-up

• Conduct laboratory testing prior to and during treatment to monitor for complications.

Risks

• Monitor for adverse events such as pneumonia, aspiration pneumonia, and malnutrition.

Patient & Prescribing Data

Patients with spinal muscular atrophy, including treatment-naïve infants and transitioning patients from lower-dose regimens.

Transitioning patients may receive a single high-dose loading phase followed by maintenance dosing.

Clinical Best Practices

• Ensure healthcare professionals are trained in lumbar puncture procedures for intrathecal administration.
• Regularly assess motor function using standardized tests during treatment.

References

• Biogen